{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069045","form_type":"8-K","ticker":null,"cik":"0001496323","company_name":"IGM Biosciences, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.251703+00:00","generated_at":"2026-06-07T15:32:06.107156+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IGM Biosciences halts hematologic oncology programs, cuts workforce 22%, extends cash runway to Q2 2026","bullets":["Reduces workforce by ~22%; focusing on DR5 agonist in colorectal cancer and T cell engagers in autoimmune diseases.","Halts all hematologic oncology clinical development and targeted cytokine program; continues Sanofi collaboration.","Plans to file IND for IGM-2644 (CD38 x CD3) for autoimmune disease in 2024.","Cash runway now expected into Q2 2026; estimates $1.9M in employee-related restructuring charges.","Enrollment continues in randomized aplitabart colorectal cancer trial (goal ~110 patients by Q1 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069045","json":"https://secwatch.observer/filing/0000950170-23-069045.json","markdown":"https://secwatch.observer/filing/0000950170-23-069045.md","text":"https://secwatch.observer/filing/0000950170-23-069045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/0000950170-23-069045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/igms-20231205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:32:06.107156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a45944a76c52a86fd8c57f66cf2084fab66d969a","claim":"IGM Biosciences, Inc. announced a restructuring with charges of approximately $1.9 million (approximately 22 percent).","evidence_excerpt":"The Company estimates it will incur approximately $1.9 million in employee-related restructuring charges as a result of the Strategic Refocusing, consisting of cash expenditures of $3.9 million from one-time employee benefits and severance costs, offset by non-cash benefits of $2.0 million related to the reversal of previously recognized incentive and stock-based compensation expense.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/0000950170-23-069045-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.9 million"},{"label":"Headcount","value":"approximately 22 percent"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}